Published in Ann Rheum Dis on January 05, 2015
Imaging Biomarkers in Crohn's Associated Spondyloarthritis (MaRCH-on) | NCT02709694
Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study. Arthritis Res Ther (2016) 1.40
Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis. PLoS One (2017) 1.39
Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol (2015) 1.11
Drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing? Ann Rheum Dis (2015) 1.07
Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013. Am J Cardiol (2015) 0.94
Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res (2015) 0.84
Impact of tofacitinib on patient outcomes in rheumatoid arthritis - review of clinical studies. Patient Relat Outcome Meas (2016) 0.79
Psoriasis and Cardiovascular Risk: Strength in Numbers Part 3. J Invest Dermatol (2015) 0.79
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. J Clin Aesthet Dermatol (2016) 0.77
Response to: 'drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?' by Dr Boers. Ann Rheum Dis (2015) 0.77
Inflammation as a Risk of Developing Chronic Kidney Disease in Rheumatoid Arthritis. PLoS One (2016) 0.77
Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Ther Adv Musculoskelet Dis (2016) 0.76
[Treatment of cardiovascular risk factors]. Z Rheumatol (2016) 0.76
The challenging interplay between rheumatoid arthritis, ageing and comorbidities. BMC Musculoskelet Disord (2016) 0.76
Improvement in HDL Function in Early Rheumatoid Arthritis Patients Treated with Methotrexate Monotherapy or Combination Therapy in the TEAR Trial. Arthritis Rheumatol (2016) 0.76
Making the next steps in psoriatic arthritis management: current status and future directions. Ther Adv Musculoskelet Dis (2015) 0.76
Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis (2017) 0.75
Author'S reply. Cent European J Urol (2015) 0.75
Rheumatoid arthritis: TNF inhibitors and cardiovascular risk management in RA. Nat Rev Rheumatol (2016) 0.75
Rheumatoid arthritis - an update for general dental practitioners. Br Dent J (2016) 0.75
Glycosylation Signatures of Inflammation Identify Cardiovascular Risk: Some Glyc It Hot. Circ Res (2016) 0.75
Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. Dtsch Arztebl Int (2017) 0.75
Serum Resistin Level and Progression of Atherosclerosis during Glucocorticoid Therapy for Systemic Autoimmune Diseases. Metabolites (2016) 0.75
Cardiovascular risk assessment in rheumatoid arthritis - controversies and the new approach. Reumatologia (2016) 0.75
Psoriasis comorbidities: complications and benefits of immunobiological treatment. An Bras Dermatol (2017) 0.75
Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis. Int J Clin Rheumtol (2015) 0.75
Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients. Biomark Res (2015) 0.75
Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis. Atherosclerosis (2016) 0.75
Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. RMD Open (2016) 0.75
Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations. Ther Adv Musculoskelet Dis (2016) 0.75
Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain. Rheumatol Int (2017) 0.75
Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. Sci Rep (2017) 0.75
Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk. Rheumatol Int (2016) 0.75
[Coxibs]. Z Rheumatol (2016) 0.75
Coronary Plaque Characterization in Psoriasis Reveals High Risk Features Which Improve Following Treatment in a Prospective Observational Study. Circulation (2017) 0.75
Association between eczema and major cardiovascular outcomes in population-based studies: a systematic review protocol. BMJ Open (2017) 0.75
Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China. Clin Rheumatol (2017) 0.75
Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study. Ther Adv Musculoskelet Dis (2017) 0.75
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med (2009) 35.37
What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA (1998) 26.79
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet (2002) 9.66
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (2011) 6.89
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis (2009) 5.82
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med (1990) 5.65
Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med (2004) 3.36
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2007) 3.34
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med (2002) 3.24
Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation (2012) 2.74
The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum (2005) 2.74
Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med (2004) 2.39
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis (2010) 2.39
Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med (2012) 2.39
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther (2006) 2.28
Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis (2012) 2.24
The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol (2011) 2.22
Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol (2011) 2.20
Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum (2008) 2.19
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol (2005) 2.17
Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum (2005) 2.14
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) (2009) 1.99
Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum (2006) 1.99
Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol (2012) 1.97
No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2010) 1.73
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum (2008) 1.73
Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum (2013) 1.72
All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis (2007) 1.68
Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum (2007) 1.67
Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol (2010) 1.67
Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) (2011) 1.55
Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol (2005) 1.53
Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Transl Res (2010) 1.52
Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J (1991) 1.50
The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum (2008) 1.44
Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study. J Invest Dermatol (2013) 1.39
Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther (2011) 1.35
Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) (2010) 1.34
Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) (2005) 1.20
From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol (2013) 1.17
Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) (2008) 1.12
Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J (2008) 1.10
Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) (2012) 1.10
Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol (2014) 1.07
Comparative effectiveness of pain management interventions for hip fracture: a systematic review. Ann Intern Med (2011) 1.07
Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med (2013) 1.01
Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis (2013) 1.01
Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation (2001) 0.96
Risk of cerebrovascular disease associated with the use of glucocorticoids in patients with incident rheumatoid arthritis: a population-based study. Ann Rheum Dis (2011) 0.95
Rofecoxib for rheumatoid arthritis. Cochrane Database Syst Rev (2005) 0.94
Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study. Arthritis Rheum (2011) 0.91
Cardiovascular comorbidities antedating the diagnosis of rheumatoid arthritis. Ann Rheum Dis (2012) 0.87
Cardiovascular adverse effects of anti-inflammatory drugs. Antiinflamm Antiallergy Agents Med Chem (2013) 0.86
Methotrexate reduces the occurrence of cerebrovascular events among Taiwanese psoriatic patients: a nationwide population-based study. Acta Derm Venereol (2012) 0.83
Cardiovascular risk and psoriasis: beyond the traditional risk factors. Am J Med (2013) 0.82
Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis (2012) 0.81
Emerging anti-inflammatory therapies for atherosclerosis. Curr Pharm Des (2013) 0.81
Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des (2014) 0.80
Important issues at heart: cardiovascular risk management in rheumatoid arthritis. Ther Adv Musculoskelet Dis (2013) 0.78
Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris. PLoS One (2016) 1.41
Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. J Allergy Clin Immunol (2015) 0.85
Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials. Arthritis Care Res (Hoboken) (2015) 0.79
Psoriasis and Smoking: A Systematic Literature Review and Meta-Analysis With Qualitative Analysis of Effect of Smoking on Psoriasis Severity. J Cutan Med Surg (2015) 0.79
Response to: 'drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?' by Dr Boers. Ann Rheum Dis (2015) 0.77
Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. J Am Acad Dermatol (2016) 0.76
Finger pad tophi in a patient with Raynaud phenomenon. JAAD Case Rep (2017) 0.75
The Association of Serum Total Peptide YY (PYY) with Obesity and Body Fat Measures in the CODING Study. PLoS One (2014) 0.75
Research Techniques Made Simple: Assessing Risk of Bias in Systematic Reviews. J Invest Dermatol (2016) 0.75
Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis. J Allergy Clin Immunol (2017) 0.75
Cyclosporine in the management of poststreptococcal pustulosis. JAMA Dermatol (2015) 0.75
Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise. J Am Acad Dermatol (2017) 0.75